Progression-free survival ratio as end point for phase II trials in advanced solid tumors

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages

  Buyse, Marc ^a   Quinaux, Emmanuel ^a   Hendlisz, Alain ^b   Golfinopoulos, Vassilis ^b   Tournigand, Christophe ^c   Mick, Rosemarie ^d  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN;

CANCER CONTROL; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; TUMOR VOLUME;

CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS;

EID: 79957487708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0380     Document Type: Letter

References (11)

1. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010
2. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079-1086, 1998 (Pubitemid 28213317)
3. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21:343-359, 2000 (Pubitemid 30456294)
4. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
5. Doroshow JH: Selecting systemic cancer therapy one patient at a time: Is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28:4869-4871, 2010
6. Bonetti A, Zaninelli M, Leone R, et al: Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann Oncol 12:187-191, 2001 (Pubitemid 32223866)
7. Comella P, Casaretti R, Crucitta E, et al: Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: A salvage regimen for colorectal cancer patients. Br J Cancer 86:1871-1875, 2002
8. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005 (Pubitemid 41132637)
9. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006 (Pubitemid 44275331)
10. Karrison TG, Maitland ML, Stadler WM, et al: Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007
11. Bruno R, Claret L: On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86:136-138, 2009